Zentalis Pharmaceuticals
Stock Forecast, Prediction & Price Target
Zentalis Pharmaceuticals Financial Estimates
Zentalis Pharmaceuticals Revenue Estimates
Zentalis Pharmaceuticals EBITDA Estimates
Zentalis Pharmaceuticals Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $1.60M Low: $1.60M High: $1.61M avg. 0% | Avg: $19.00M Low: $18.97M High: $19.12M avg. 1082.98% | Avg: $111.85M Low: $111.69M High: $112.58M avg. 488.53% | Avg: $271.55M Low: $271.16M High: $273.32M avg. 142.77% |
Net Income
% change YoY
| $-164.26M N/A | $-220.83M -34.43% | $-292.19M -32.31% | Avg: $-297.05M Low: $-267.52M High: $-181.83M avg. -1.66% | Avg: $-317.45M Low: $-281.25M High: $-144.55M avg. -6.86% | Avg: $-162.73M Low: $-164.11M High: $-162.43M avg. 48.73% | Avg: $-68.81M Low: $-69.39M High: $-68.68M avg. 57.71% |
EBITDA
% change YoY
| $-268.52M N/A | $-233.27M 13.12% | $-275.50M -18.10% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$3.85 N/A | -$4.18 -8.57% | -$4.47 -6.93% | Avg: -$3.69 Low: -$4.09 High: -$2.78 avg. 17.55% | Avg: -$3.34 Low: -$4.3 High: -$2.21 avg. 9.35% | Avg: -$2.49 Low: -$2.51 High: -$2.48 avg. 25.51% | Avg: -$1.05 Low: -$1.06 High: -$1.05 avg. 57.71% |
Operating Expenses
% change YoY
| $216.54M N/A | $227.28M 4.96% | $252.55M 11.11% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Zentalis Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 24.48% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -267.52M, average is -297.05M and high is -181.83M.
What is Zentalis Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 428.57% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $1.60M, average is $1.60M and high is $1.61M.
What is Zentalis Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 27.53% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$4.09, average is -$3.69 and high is $-2.78.
What is the best performing analyst?
In the last twelve months analysts have been covering Zentalis Pharmaceuticals stock. The most successful analyst is Matthew Harrison.